A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...

GLP-1 receptor agonist prescriptions increased significantly during study period across all categories of BMI, in dose-response manner.

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

As demand soared for weight-loss drugs, price signals worked.

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Advances recognized by science’s most lucrative awards include high-energy physics experiments and groundbreaking weight-loss ...

The weight-loss drug revolution has arrived, and the food & beverage industry has begun to evolve in response to suppressed ...

Ozempic and similar semaglutide-based medications have been hailed as miracle drugs. Known as GLP-1 (glucagon-like peptide-1) ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

In a plenary session at the annual American Academy of Neurology meeting, Paul Edison, MD, PhD, of Imperial College London in England, assessed how GLP-1 receptor agonists might influence cognitive ...

GLP-1RA use was associated with lower all-cause mortality and hospitalizations among patients with T2D and comorbid atrial fibrillation.

In people with type 2 diabetes, both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) were statistically significantly associated with ...